arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Bausch Health Companies Inc.

BHC
$6.25 ▲ +0.34 (+5.75%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
19 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
56
Health
Fair
Moderately Bearish
auto_awesome

Analytical Summary

Bausch Health Companies Inc. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $2.3B
Dividend Yield
Revenue Growth 6.7%
Op. Margin 17.7%
ROIC 2.9%
FCF / Share $2.70
Trailing P/E 14.9x
Price / Book
FCF Yield 43.3%
Debt / Equity -37.58
info Valuation on last close. End-of-day price, Aug 7, 2026.

19-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$10.27B
↑ +6.7%
Net Income Profit after all expenses
$157.00M
↑ +441.3%
Operating Margin Operating profit as % of sales
17.7%
↑ +9.9% 71th
FCF / Share Free cash flow per share
$2.70
↓ -21.0%
Long-Term Debt Long-term obligations
$20.82B
↓ -3.7%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
56
Returns
24
Financial Health
77
Cash Quality
96

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 19 years · 72 quarters